En este artculo vamos a ver qu es el GLP-1, cmo acta en el organismo, qu dice la ciencia sobre su uso en el fitness y si puede ser una herramienta vlida en estrategias de prdida de grasa, recomposicin corporal o mejora del rendimiento
The FDA accepted the supplemental BLA to move the drug into the frontline setting on June 6 and set a target action date of Sept
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - The Lancet, Diabetes & Endocrinology Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss - Diabetes, Obesity & Metabolism Once-Weekly Semaglutide in Adults with Overweight or Obesity - The New England Journal of Medicine Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity - Diabetes, Obesity & Metabolism Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus - Journal of Clinical Medicine Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss - JAMA
GSK3, glycogen synthase kinase 3
The authors analyze the first results of the ongoing PRIN (Research Project of Significant National Interest) project RE-PLACE
